The FDA has documented several concerns specifically involving compounded GLP-1 products: dosing errors (including doses far exceeding the FDA-approved label), improper storage during shipping affecting medication integrity, reports of fraudulent or counterfeit compounded products, adverse event reports associated with compounded GLP-1 use, and the use of semaglutide salt forms (such as semaglutide sodium or semaglutide acetate) that should not be used for compounding
It acts on three pathways regulating appetite and metabolism
Providers should rely on FDA labeling, and applicable state and federal regulations when prescribing or administering GLP-1 medications
Although our data align with the notion that inhibiting NMDA receptor signalling in the hypothalamus decreases food intake and body weight 8,40 , earlier studies have demonstrated that NMDA receptor antagonism in the brainstem attenuates vagus-mediated meal-related satiety 6,7,42
This delayed emptying helps control blood glucose and regulate appetite but can create conditions where food remains in the digestive tract longer than usual
Do GLP-1 receptor agonists have cardiovascular benefits
